Amway announced its intention to grow its collaboration with South Korea-based HEM Pharma. This announcement follows a decade of groundbreaking collaboration between the companies since Amway first initiated research and collaboration with HEM in 2016. The companies have reinforced their shared commitment to advancing joint scientific research, technology, and services in the field of microbiome health across the more than 100 countries and territories where Amway conducts business.
Together, Amway, alongside its Amway Business Owners (ABOs), and HEM have developed one of the largest gut microbiome databases in the world with more than 90,000 participants in South Korea. This robust dataset has driven valuable health insights and informed strategic growth initiatives.
“As part of Amway’s continued vision to help people live better lives, we’re committed to uncovering new insights that inspire innovative lifestyle, product and service solutions, empowering ABOs and enhancing the Amway customer experience worldwide,” said Amway Chief Research & Development Officer Kristi Pelc.
Amway will extend its microbiome research efforts to additional key markets including Japan, Thailand, Malaysia, Taiwan, and the United States.
For Amway, this marks the first and a strategically significant collaboration centered on delivering microbiome-based technologies and services to support healthier living.
Leave a Reply